Parnax Lab Limited (BOM:506128)

Market Cap	1.74B +65.6%
Revenue (ttm)	2.28B +23.1%
Net Income	125.20M +15.5%
EPS	10.90 +15.5%
Shares Out	11.49M
PE Ratio	13.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,111
Open	145.00
Previous Close	145.15
Day's Range	142.50 - 149.95
52-Week Range	90.17 - 182.00
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provid...

• Industry: Pharmaceutical Preparations
• Founded: 1982
• Employees: 12
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506128

Financial Performance

In fiscal year 2025, Parnax Lab's revenue was 1.88 billion, a decrease of -0.54% compared to the previous year's 1.89 billion. Earnings were 115.19 million, an increase of 19.87%.